Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on infectious disease, today announced it has appointed Mitchel Sayare, Ph.D., as Executive Chairman of the Board, effective immediately.
Johns Hopkins spinout Clear Guide Medical received a $2 million grant from the National Institutes of Health to apply its imaging tools to pediatrics.
A Baltimore biotechnology company has raised $4 million, to help bring its therapeutic treatment targeting rare genetic diseases closer to market.
Venture funding for Greater Washington companies fell nearly 50 percent in the second quarter from a year ago, but the region’s take for the first half of the year remains above last year.
The National Institute of Standards and Technology issued a request for information seeking ideas for improving the public’s return on investment from federally supported R&D. Here’s my submission.
WellDoc®, a leading digital health company, today announces hypertension and weight management solutions integrated within its digital therapeutic app for type 2 diabetes, BlueStar®. Later this year, WellDoc will launch its stand-alone product for individuals living with hypertension (high blood pressure) and stand-alone products are also in development for multiple chronic diseases.
The Washington area is rarely thought of as a hotbed for technology companies. The region’s biggest firms have generally gravitated toward the quiet, stable business of government contracting, while start-ups tend to move elsewhere in search of growth capital.
Teva Pharmaceutical Industries Ltd., the troubled Israeli manufacturer of generic drugs, will be moving its US headquarters from Pennsylvania to New Jersey, lured by 10-year, $40 million tax incentive plan.
Attending the Farm Progress Show at Boone, Iowa, this year? Add the Iowa AgriTech Accelerator to your list of exhibitors to visit.
When Viela Bio spun out of MedImmune in March, it started with six assets — three in clinical trials and three in preclinical development — putting it ahead of most startups and many spin-offs. “Other spin-offs often are developing assets that have been shelved for various reasons or that have been deprioritized,” Bing Yao, Ph.D., CEO, notes. “But for Viela Bio, this is a continuation of the programs, not a handoff.”